Navidea Biopharmaceuticals Buy Hold or Sell Recommendation
| NAVBDelisted Stock | USD 0.1 0.01 9.45% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Navidea Biopharmaceuticals is 'Not Rated'. Macroaxis provides Navidea Biopharmaceutica buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding NAVB positions.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. In addition, we conduct extensive research on individual companies such as Navidea and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Navidea Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real.
Navidea |
Execute Navidea Biopharmaceutica Buy or Sell Advice
The Navidea recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Navidea Biopharmaceuticals. Macroaxis does not own or have any residual interests in Navidea Biopharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Navidea Biopharmaceutica's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Not Rated
Navidea Biopharmaceutica Trading Alerts and Improvement Suggestions
| Navidea Biopharmaceutica is not yet fully synchronised with the market data | |
| Navidea Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Navidea Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Navidea Biopharmaceuticals currently holds 2.43 M in liabilities with Debt to Equity (D/E) ratio of 1.2, which is about average as compared to similar companies. Navidea Biopharmaceutica has a current ratio of 0.22, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Navidea Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Navidea Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Navidea Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Navidea to invest in growth at high rates of return. When we think about Navidea Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 65.65 K. Net Loss for the year was (15.18 M) with loss before overhead, payroll, taxes, and interest of (119.3 K). | |
| Navidea Biopharmaceuticals currently holds about 328.01 K in cash with (8.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 35.0% of Navidea Biopharmaceutica outstanding shares are owned by corporate insiders |
Navidea Biopharmaceutica current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Navidea analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Navidea analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Navidea Biopharmaceutica Returns Distribution Density
The distribution of Navidea Biopharmaceutica's historical returns is an attempt to chart the uncertainty of Navidea Biopharmaceutica's future price movements. The chart of the probability distribution of Navidea Biopharmaceutica daily returns describes the distribution of returns around its average expected value. We use Navidea Biopharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Navidea Biopharmaceutica returns is essential to provide solid investment advice for Navidea Biopharmaceutica.
| Mean Return | -1.1 | Value At Risk | -12.5 | Potential Upside | 12.50 | Standard Deviation | 8.36 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Navidea Biopharmaceutica historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Note: Acquisition or disposition of Navidea Biopharmaceutica securities by Scott John K Jr [view details]
Navidea Biopharmaceutica Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Navidea . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Navidea Biopharmaceutica Buy or Sell Advice
When is the right time to buy or sell Navidea Biopharmaceuticals? Buying financial instruments such as Navidea Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Navidea Biopharmaceutica in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Long Short Funds Thematic Idea Now
Long Short Funds
Funds or Etfs that are designed to hedge away market risk by investing in combination of bonds, stocks, derivative instruments as well as short positions to maximize returns irrespective of market conditions. The Long Short Funds theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Long Short Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Navidea Pink Sheet
If you are still planning to invest in Navidea Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Navidea Biopharmaceutica's history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Stocks Directory Find actively traded stocks across global markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |